(Adds detail from ChinaWhys report) By John Ruwitch, Adam Jourdan and Ben Hirschler SHANGHAI/LONDON, June 30 (Reuters) - GlaxoSmithKline Plc's tangled web of problems in China, including a sex video of its former China chief and anonymous emails alleging corruption, are highlighted i
Read moreGlaxoSmithKline (GSK) on Monday announced that in partnership with US-listed Theravance it has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for two different doses of an asthma treatment taken through its Ellipta dry powder inhaler. The filing o
Read moreLONDON, June 29 (Reuters) - GlaxoSmithKline on Sunday confirmed the existence an intimate video recording of its former China head Mark Reilly, which the Sunday Times reported kicked off a bribery investigation that has damaged the drugmaker's business in China. The Sunday Times said the re
Read moreOver the longer-term, say five to ten years, it would be reasonable to expect borrowing costs to rise back to their pre-recesssion levels, of about 5%, but "it's probably quite a long way down the road" outgoing Bank of England Deputy Charlie Bean told Sky News in an interview. That comes after Gove
Read moreJune 27 (Reuters) - GlaxoSmithKline Plc and Genmab A/S said on Friday their cancer drug Arzerra failed to treat a type of leukemia more effectively than other drugs in a late-stage trial. Arzerra, known chemically as ofatumumab, was being tested in patients with a type of blood cancer known
Read moreGlaxoSmithKline (GSK) shares moved higher on Friday after ViiV Healthcare, the HIV-focused business jointly owned with Pfizer, took a step forward in the marketing authorisation process for its Triumeq treatment. Based on two studies, the Committee for Medicinal Products for Human Use of the Europe
Read more